Uncategorized
CHMP recommends change in terms of marketing authorization for Nevanac
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending a change to the terms of the marketing authorization for Nevanac, according to a summary of opinion from the European Medicines Agency. The recommended change is an extended indication that states “Nevanac 3 mg/mL is indicated in adults for prevention and treatment of postoperative pain and inflammation associated with cataract surgery [and] reduction in the risk of preoperative macular edema associated with cataract surgery in diabetic patients,” the opinion said.